S.A. Mason’s Inovio Pharmaceuticals INO Stock Holding History

S.A. Mason’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-313	Closed	-$1.91K	–	317
2023 Q4	$1.91K	Hold	313	–	–	﹤0.01%	310
2023 Q3	$1.46K	Hold	313	–	–	﹤0.01%	310
2023 Q2	$3.08K	Hold	313	–	–	﹤0.01%	310
2023 Q1	$3.08K	Hold	313	–	–	﹤0.01%	310
2022 Q4	$5.85K	Hold	313	–	–	﹤0.01%	301
2022 Q3	$6K	Hold	313	–	–	﹤0.01%	308
2022 Q2	$6K	Hold	313	–	–	﹤0.01%	315
2022 Q1	$13K	Hold	313	–	–	0.01%	306
2021 Q4	$19K	Hold	313	–	–	0.01%	294
2021 Q3	$27K	Hold	313	–	–	0.02%	281
2021 Q2	$35K	Hold	313	–	–	0.02%	267
2021 Q1	$35K	Hold	313	–	–	0.03%	261
2020 Q4	$33K	Hold	313	–	–	0.03%	250
2020 Q3	$44K	Hold	313	–	–	0.04%	217
2020 Q2	$101K	Hold	313	–	–	0.11%	165
2020 Q1	$28K	Sell	313 -333	-52%	-$20.5K	0.03%	245
2019 Q4	$26K	Buy	+646	New	+$19.4K	0.02%	277

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

S.A. Mason's INO Position: Q1 2024 in Review

S.A. Mason sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 313 shares — an estimated $1.91K sold.

S.A. Mason first reported a position in INO in Q4 2019 and held it in 17 quarters. The position peaked at $101K in Q2 2020. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

S.A. Mason reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
S.A. Mason sold 313 Inovio Pharmaceuticals shares in Q1 2024, an estimated $1.91K.
S.A. Mason first reported a position in Inovio Pharmaceuticals in Q4 2019 and held it in 17 quarters.
S.A. Mason's Inovio Pharmaceuticals position peaked at $101K in Q2 2020.
89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on S.A. Mason's 13F filing for Q1 2024, filed 15 Apr 2024.